2.25
전일 마감가:
$2.29
열려 있는:
$2.22
하루 거래량:
222.24K
Relative Volume:
0.90
시가총액:
$117.55M
수익:
$81.06M
순이익/손실:
$-55.55M
주가수익비율:
-1.9737
EPS:
-1.14
순현금흐름:
$-47.98M
1주 성능:
-15.70%
1개월 성능:
-14.91%
6개월 성능:
-63.51%
1년 성능:
-58.55%
Sight Sciences Inc Stock (SGHT) Company Profile
명칭
Sight Sciences Inc
전화
(415) 889-0550
주소
4040 CAMPBELL AVE,, MENLO PARK
SGHT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SGHT
Sight Sciences Inc
|
2.25 | 117.55M | 81.06M | -55.55M | -47.98M | -1.14 |
![]()
ABT
Abbott Laboratories
|
131.54 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
99.99 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
376.10 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
88.56 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
71.75 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-06 | 개시 | UBS | Buy |
2024-11-04 | 다운그레이드 | Lake Street | Buy → Hold |
2024-08-21 | 개시 | Lake Street | Buy |
2023-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2023-09-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2023-09-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2023-08-24 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
2023-01-06 | 업그레이드 | Stifel | Hold → Buy |
2022-10-04 | 개시 | Needham | Hold |
2022-07-26 | 개시 | Stifel | Hold |
2022-02-03 | 개시 | William Blair | Outperform |
2022-01-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Sight Sciences Inc 주식(SGHT)의 최신 뉴스
Charles Schwab Investment Management Inc. Raises Stock Position in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Sight sciences chief legal officer sells shares worth $19,250 - MSN
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th - GlobeNewswire
Key Investor Updates Coming: Sight Sciences Takes Center Stage at Major Healthcare Conference - Stock Titan
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Sight sciences EVP Manohar Raheja buys $53,250 in stock By Investing.com - Investing.com Australia
Sight sciences EVP Manohar Raheja buys $53,250 in stock - Investing.com India
Lake Street Capital Cuts Sight Sciences (NASDAQ:SGHT) Price Target to $2.50 - The AM Reporter
Sight Sciences’ (SGHT) Hold Rating Reiterated at Needham & Company LLC - Defense World
Piper Sandler Cuts Sight Sciences (NASDAQ:SGHT) Price Target to $3.50 - Defense World
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics - MSN
Lake Street Capital Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Stifel Nicolaus Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts By Investing.com - Investing.com Australia
Actinic Keratosis Market Forecast 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Treatment, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Sight Sciences Inc. (SGHT) reports earnings - Quartz
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results, Initiates Full Year 2025 Financial Guidance - Vision Monday
Sight Sciences Faces Headwinds in Glaucoma and Dry Eye Markets, Hold Rating Maintained - TipRanks
Sight Sciences’ Earnings Call: Cautious Optimism Amid Challenges - TipRanks
Sight Sciences price target lowered to $3.50 from $5.50 at Piper Sandler - TipRanks
Stifel cuts Sight Sciences price target to $4, maintains Buy rating By Investing.com - Investing.com South Africa
Stifel cuts Sight Sciences price target to $4, maintains Buy rating - Investing.com
Sight Sciences Stock Hits 52-Week Low at $2.27 Amid Market Challenges - Investing.com India
Sight Sciences Stock Hits 52-Week Low at $2.27 Amid Market Challenges By Investing.com - Investing.com South Africa
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2024 Earnings Call Transcript - Insider Monkey
Citigroup Lowers Sight Sciences (NASDAQ:SGHT) Price Target to $3.00 - Defense World
Sight Sciences Reports 2024 Results and 2025 Outlook - TipRanks
Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts - Investing.com India
Sight Sciences Expects 2025 Revenue To Decline By 6% To 12% - Nasdaq
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Sight Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sight Sciences Reports 2024 Financial Results and 2025 Outlook - TipRanks
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance - The Manila Times
Sight Sciences earnings missed by $0.01, revenue fell short of estimates - Investing.com UK
Sight Sciences Reports Fourth Quarter and Full Year 2024 - GlobeNewswire
Breaking Down Sight Sciences: 6 Analysts Share Their Views - Benzinga
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Sight Sciences Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Sight Sciences (SGHT) Projected to Post Earnings on Wednesday - Defense World
Sight Sciences (SGHT) to Release Quarterly Earnings on Wednesday - MarketBeat
Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know - MSN
Institutional owners may consider drastic measures as Sight Sciences, Inc.'s (NASDAQ:SGHT) recent US$14m drop adds to long-term losses - Simply Wall St
Sight Sciences To Present Clinical Data On OMNI Surgical System At AGS Annual Meeting 2025 - Nasdaq
Sight Sciences stock hits 52-week low at $2.47 amid market challenges - Investing.com Nigeria
Sight Sciences to Present Comprehensive Clinical Data on - GlobeNewswire
Can This Groundbreaking Glaucoma Treatment Transform Patient Care? New Data Reveals 3-Year Outcomes - StockTitan
Sight Sciences stock hits 52-week low at $2.47 amid market challenges By Investing.com - Investing.com South Africa
Sight Sciences Inc (SGHT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):